Apr 25 2013
Sensimed AG, announced today that 10 scientific publications reporting outcomes of clinical studies investigating the use of SENSIMED Triggerfish® will be presented at ARVO 2013. The company developed the SENSIMED Triggerfish®, a revolutionary contact lens for the continuous recording of the 24-hour intraocular pressure (IOP) pattern to facilitate the management of glaucoma.
SENSIMED Triggerfish
A total of 9 posters were accepted for presentation by the 2013 ARVO Annual Meeting Program Committee. These will be reporting on the use of the SENSIMED Triggerfish® in clinical studies in various locations worldwide. The Poster sessions are titled "Ocular Nanotechnology, Nanoparticles, and Gene Therapy" and "Glaucoma: Intraocular Pressure" and are scheduled in the morning of May 6th and May 9th 2013 respectively.
In addition Sensimed was selected for an oral presentation during the "Nanotechnology and Regenerative Medicine Group: Minimally invasive biometric technology as a means to improve detection, understanding, and treatment of ocular disease" portion of the symposium.
"We are proud to have been selected to present our research on the SENSIMED Triggerfish® to the scientific community at ARVO, especially considering the large number of applicants." commented Jean-Marc Wismer, Chief Executive Officer of Sensimed. "This year's ARVO meeting provides a unique platform for Sensimed to share the continued research with our peers" said René Goedkoop, MD, Chief Medical Officer of Sensimed, "Especially in light of the mounting interest for SENSIMED Triggerfish® in conjuncture with the progressive increase of significant data from clinical studies."
The ARVO congress will take place in Seattle from May 5th to 9th 2013 focusing on encouraging and assisting research, training, publication and knowledge sharing in vision and ophthalmology. With more than 12'000 researchers from over 80 countries, the ARVO is the largest and most respected eye and vision organization.
FROM DEVICE TO KNOWLEDGE -- Sensimed AG, a Swiss company, has developed a non-invasive soft contact lens-based solution, the SENSIMED Triggerfish® that revolutionizes glaucoma management by providing continuous 24 hour intraocular pressure (IOP) profiles as well as modeling and analysis of IOP patterns. The 24 hour IOP profiles, centralized on a registry together with patient and treatment information, are processed by powerful modeling and learning algorithms identifying pathological patterns that can be used to differentiate indication and to personalize treatment. Sensimed is directly positioned at the convergence between devices, treatment and information. The company believes that this global knowledge-building approach will enable ophthalmologists to better improve management of patients with potentially progressive glaucoma.
Source: http://www.sensimed.ch/